MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$17,120
Net Income
-$2,867,303
Net Profit Margin
-16748.27%
EPS
-$1.28
Unit: Dollar
Revenue Breakdown
CH
GB
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
17,120
21,457
303,596
303,651
Cost of revenue
12,817
23,112
55,912
34,757
Gross profit
4,303
-1,655
247,684
268,894
Selling, general, and administrative
2,245,653
2,039,328
1,504,758
2,341,347
Research and development
3,440
50,818
24,293*
-3,211
Impairment of entadfi assets
-
-
0*
0
Impairment of intangibles
-
-
0*
-
Impairment of goodwill
486,000
8,134,000
0
0
Total operating expenses
2,735,093
10,224,146
1,529,051
2,338,136
Loss from operations
-2,730,790
-10,225,801
-1,281,367
-2,069,242
Gain on extinguishment of note payable
-
-
2,158,910.75*
-5,384,719
Gain on issuance of preferred stock and warrants
-
-
-3,955,658*
2,543,329
Gain on extinguishment of preferred stock
-
-
-392,488*
196,244
Interest expense
4,389
2,244
4,247
300,069
Interest expense related party
-
-
0*
0
Interest income
-
-
0.5*
-
Change in fair value of subscription agreement liability
-
-
0
0
Change in fair value of contingent warrant liabilities
400
-1,612
-16,607*
36
Change in fair value of warrant liabilities
-
-
-
-1,934,000
Change in fair value of series d warrant liability
-
-
2,594,409.5*
-
Change in fair value of series d derivative liability
136,471
-3,955,778
3,161,333*
216,000
Change in fair value of series e warrant liability
-
-
-1,121,711.75*
-
Change in fair value of series e derivative liability
-
-2,072,590
384,753.5*
-
Gain on forgiveness of accounts payable
-
-
0
0
Other income (loss)
4,747
-16,810
262,127
-8,063
Total other income (loss)
-136,513
6,010,926
6,951,579
-6,714,460
Gain before income taxes
-2,867,303
-4,214,875
5,670,212
-8,783,702
Income tax (expense) benefit
-
-
525
0
Net gain
-2,867,303
-4,214,875
5,669,687
-8,783,702
Deemed dividend series c preferred stock
-
-
0
0
Net gain applicable to common stockholders
-2,867,303
-4,214,875
5,669,687
-8,783,702
Basic EPS
-1.28
-6.71
6.046
-6.25
Diluted EPS
-1.28
-6.71
6.046
-6.25
Basic Average Shares
2,242,770
628,528
937,690*
1,405,469
Diluted Average Shares
2,242,770
628,528
937,690*
1,405,469
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net gain applicable
to common...
-$2,867,303
(-6.16%↓ Y/Y)
Net gain
-$2,867,303
(-20.86%↓ Y/Y)
CH
$10,322
GB
$6,798
Gain before income
taxes
-$2,867,303
(-20.86%↓ Y/Y)
Revenue
$17,120
(-83.92%↓ Y/Y)
Loss from operations
-$2,730,790
(-41.10%↓ Y/Y)
Total other income
(loss)
-$136,513
(68.76%↑ Y/Y)
Gross profit
$4,303
(-93.90%↓ Y/Y)
Other income (loss)
$4,747
(120.95%↑ Y/Y)
Cost of revenue
$12,817
(-64.39%↓ Y/Y)
Total operating
expenses
$2,735,093
(36.35%↑ Y/Y)
Change in fair value of
series d derivative...
$136,471
Interest expense
$4,389
(-98.03%↓ Y/Y)
Change in fair value of
contingent warrant...
$400
(74.67%↑ Y/Y)
Selling, general, and
administrative
$2,245,653
(47.39%↑ Y/Y)
Impairment of goodwill
$486,000
(-18.18%↓ Y/Y)
Research and development
$3,440
(103.08%↑ Y/Y)
Buy us a coffee
Onconetix, Inc. (ONCO)
Onconetix, Inc. (ONCO)